





Arch Biopartners

www.archbiopartners.com

ACH-CNSX

THE SMALL CAP CONFERENCE
October 28, 2010, Vancouver





Disclaimer Regarding Forward-Looking Statements

This presentation contains forward-looking statements and other information that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Arch Biopartners Inc (“Company”). There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change; however, these risks may be detailed from time to time in the Company’s public disclosures.

Prospective purchasers are responsible for their own due diligence regarding any investment in the Company.

ACH-CNSX

FOIFF-US OTC Markets



Arch Biopartners is a portfolio based biotech company developing new products and technology for sale to industrial and pharmaceutical companies.

ACH-CNSX

FOIFF-US OTC Markets



Arch Biopartners is like a mining exploration company that:

- 1) owns or acquires rights to land property
- 2) develops the land, drills holes and finds the minerals
- 3) sells the property at a profit to a bigger company.

ACH-CNSX

FOIFF-US OTC Markets




Arch Biopartners' property is *Intellectual Property* (Patents) on technologies invented at the Universities of Alberta, Colorado and Calgary.

ACH-CNSX

FOIFF-US OTC Markets

Technology Development Continuum






Stakeholders of Arch

- Jerry McElroy is Executive Chairman. He leads an experienced board having co-founded several successful companies including MDS Health Group (MDS–TSX, MDZ-NYSE) and Helix Biopharma (HBP-TSX).
- The Universities of Calgary and Alberta are shareholders in return for IP rights. The U of Colorado has a pending shareholding stake.
- 11 scientists have exchanged their rights to IP of their technology inventions in return for shares in Arch

The Interests of Insiders, Universities and Investors are Aligned

CURRENT INTELLECTUAL PROPERTIES




- Arch Biophysics (industrial focus)
- Arch Cancer Therapeutics (Brain tumours)
- Arch Inflammation (kidney and bowel diseases)
- Colorado Cancer Therapeutics (pancreatic; non small cell lung and prostate cancers)

For more information on the Arch platforms, please visit
www.archbiopartners.com

ARCH BIOPHYSICS



Focused on developing novel synthetic molecules that strongly bind to solid surfaces such as metals, plastics, silicone and latex.



Potential applications include:

- I. Making medical implants more biocompatible with the human body Ex: lowering rejection rates
- II. Anti-corrosion; increased hardness of surface

ARCH CANCER THERAPEUTICS


Targeting Brain Tumour Cells



Arch has identified novel molecules that selectively target brain tumour cells and brain tumour initiating cells (BTICs) of malignant glioma.

Applications:

- I. Brain Tumour diagnosis - use a scan like an MRI to locate brain tumour initiating cells for the first time
- II. Treatment for brain tumours – improve surgical management short term. Develop anti cancer drugs long term



ARCH INFLAMMATION

Focused on developing novel drugs that prevent or inhibit inflammation, which is at the root of many common diseases.

Potential applications include:

- I. Chronic Kidney disease
- II. Inflammatory Bowel Disease
- III. C. Difficile

COLORADO CANCER THERAPEUTICS



Formed to acquire and develop anti-cancer compounds.

- Has option to enter exclusive license for anti-cancer compounds invented at University of Colorado and Emory.
- So far, these compounds have slowed the progression of pancreatic, prostate and non-small cell lung cancer in mice.
- CCT has until Jan 1, 2012 to complete further testing and validation before option expires.

Public Facts of Note

- 47.3M common shares with 100,000 options outstanding. Last at \$0.75 per share on Oct 26, 2010.
- Approx 28M shares held by scientists, insiders and Universities of Alberta and Calgary
- Insiders did over 75% of the \$700,000 private placement at \$0.50/share on May 7, 2010 – also, first day of trading on CNSX.

ACH-CNSX

FOIFF-US OTC Markets

THE ARCH MODEL MITIGATES RISK

- Portfolio approach
- **LOW CASH BURN RATE** and controlled overhead costs due to relationships with Universities. (Ex: Alberta, Calgary and Colorado)
- Continued eligibility for government and academic grants
- Experienced business-minded management focused on sale of technology

MINIMIZING RISK WITHOUT COMPROMISING UPSIDE

Arch 
Biopartners
www.archbiopartners.com

For more info, please visit our website
or contact 647 428 7031

Email: info@archbiopartners.com

ACH-CNSX

THANK YOU

